American Journal of Kidney Diseases
Volume 55, Issue 5 , Pages 916-922 , May 2010

Carbohydrate Antigen 19-9 as a Diagnostic Marker for Hepatic Cyst Infection in Autosomal Dominant Polycystic Kidney Disease

  • Nada Kanaan, MD

      Affiliations

    • Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
    • Corresponding Author InformationAddress correspondence to Nada Kanaan, MD, Division of Nephrology, Cliniques Universitaires Saint-Luc, Av Hippocrate, 10, 1200 Brussels, Belgium
    • ,
  • Eric Goffin, MD

      Affiliations

    • Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
    • ,
  • Yves Pirson, MD

      Affiliations

    • Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
    • ,
  • Olivier Devuyst, MD, PhD

      Affiliations

    • Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
    • ,
  • Ziad Hassoun, MD

      Affiliations

    • Division of Gastroenterology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium

Received 6 July 2009 ,Accepted 18 December 2009.

References 

  1. Chauveau D, Fakhouri F, Grunfeld J-P. Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. J Am Soc Nephrol. 2000;11(9):1767–1775
  2. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 369(9569):1287-1301.
  3. Telenti A, Torres VE, Gross JB, Van Scoy RE, Brown ML, Hattery RR. Hepatic cyst infection in autosomal dominant polycystic kidney disease. Mayo Clin Proc. 1990;65(7):933–942
  4. Migali G, Annet L, Lonneux M, Devuyst O. Renal cyst infection in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2008;23(1):404–405
  5. Bleeker-Rovers CP, de Sevaux RG, van Hamersvelt HW, Corstens FH, Oyen WJ. Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2003;41(6):E18–E21
  6. Soussan M, Sberro R, Wartski M, Fakhouri F, Pecking A-P, Alberini J-L. Diagnosis and localization of renal cyst infection by 18F-fluorodeoxyglucose PET/CT in polycystic kidney disease. Ann Nucl Med. 2008;22(6):529–531
  7. Tsuji M, Kashihara T, Terada N, Mori H. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19. Pathol Int. 1999;49(4):310–317
  8. Nakajima T, Kondo Y. Well-differentiated cholangiocarcinoma: diagnostic significance of morphologic and immunohistochemical parameters. Am J Surg Pathol. 1989;13(7):569–573
  9. Kitagawa Y, Iwai M, Muramatsu A, et al. Immunohistochemical localization of CEA, CA19-9 and DU-PAN-2 in hepatitis C virus-infected liver tissues. Histopathology. 2002;40(5):472–479
  10. Yanai H, Tada N. A simple hepatic cyst with elevated serum and cyst fluid CA19-9 levels: a case report. J Med Case Reports. 2008;2:329
  11. Yoshida H, Onda M, Tajiri T, et al. Infected hepatic cyst. Hepatogastroenterology. 2003;50(50):507–509
  12. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130(6):461–470
  13. Nishihara S, Narimatsu H, Iwasaki H, et al. Molecular genetic analysis of the human Lewis histo-blood group system. J Biol Chem. 1994;269(46):29271–29278
  14. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol. 1999;10(suppl 4):145–149
  15. Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H. Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res. 1982;42(11):4820–4823
  16. La'ulu SL, Roberts WL. Performance characteristics of five automated CA 19-9 assays. Am J Clin Pathol. 2007;127(3):436–440
  17. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266–270
  18. Loy TS, Sharp SC, Andershock CJ, Craig SB. Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas (An immunohistochemical study of 527 cases). Am J Clin Pathol. 1993;99(6):726–728
  19. Mimidis K, Anagnostoulis S, Iakovidis C, Argyropoulou P. Remarkably elevated serum levels of carbohydrate antigen 19-9 in cystic duct and common bile duct lithiasis. J Gastrointest Liver Dis. 2008;17(1):111–112
  20. Ong S, Sachdeva A, Garcea G, et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci. 2008;53(12):3213–3217
  21. Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem. 1998;35(pt 1):99–103
  22. Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 2000;26(5):474–479
  23. Parra JL, Kaplan S, Barkin JS. Elevated CA 19-9 caused by Hashimoto's thyroiditis: review of the benign causes of increased CA 19-9 level. Dig Dis Sci. 2005;50(4):694–695
  24. Kodama T, Satoh H, Ishikawa H, Ohtsuka M. Serum levels of CA19-9 in patients with nonmalignant respiratory diseases. J Clin Lab Anal. 2007;21(2):103–106
  25. Del Villano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983;29(3):549–552
  26. Kim H-J, Kim M-H, Myung S-J, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol. 1999;94(7):1941–1946
  27. Iwase K, Takenaka H, Oshima S, et al. Determination of tumor marker levels in cystic fluid of benign liver cysts. Dig Dis Sci. 1992;37(11):1648–1654
  28. Everson GT, Taylor MRG, Doctor RB. Polycystic disease of the liver. Hepatology. 2004;40(4):774–782
  29. Aybek H, Aybek Z, Sinik Z, Demir S, Sancak B, Tuncay L. Elevation of serum and urinary carbohydrate antigen 19-9 in benign hydronephrosis. Int J Urol. 2006;13(11):1380–1384
  30. Meyer A, Kausch I, Krüger S, Fetscher S, Böhle A, Jocham D. Elevation of CA 19-9 in giant hydronephrosis induced by a renal calculus. Urology. 2004;63(2):381–382
  31. Shudo R, Saito T, Takahashi K, et al. Giant hydronephrosis due to a ureteral stone, and elevated serum levels of CA 19-9. Intern Med. 1999;38(11):887–891
  32. Suzuki K, Muraishi O, Tokue A. The correlation of serum carbohydrate antigen 19-9 with benign hydronephrosis. J Urol. 2002;167(1):16–20
  33. Ohshio G, Ogawa K, Kudo H, et al. Immunohistochemical distribution of CA19-9 in normal and tumor tissues of the kidney. Urol Int. 1990;45(1):1–3
  34. Akdogan M, Sasmaz N, Kayhan B, Biyikoglu I, Disibeyaz S, Sahin B. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori. 2001;87(5):337–339
  35. Sheen-Chen S-M, Sun C-K, Liu Y-W, Eng H-L, Ko S-F, Kuo C-H. Extremely elevated CA19-9 in acute cholangitis. Dig Dis Sci. 2007;52(11):3140–3142
  36. Nakamura T, Maruyama K, Kashiwabara H, et al. Diverticulitis causing a high serum level of carbohydrate antigen 19-9: report of a case. Surg Today. 2002;32(3):282–284

 Originally published online as doi:10.1053/j.ajkd.2009.12.023 on March 2, 2010.

PII: S0272-6386(09)01661-8

doi: 10.1053/j.ajkd.2009.12.023

American Journal of Kidney Diseases
Volume 55, Issue 5 , Pages 916-922 , May 2010

Article Tools

* Image Usage & Resolution